Spero Therapeutics Announces First Quarter 2023 Operating Re

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr... | May 11, 2023

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , Massachusetts , Lora Grassilli , Ankit Mahadevia , Ted Jenkins , Congress Engagement , Department Of The Army , Department Of Defense , Exchange Commission , European Congress , Nasdaq , National Institutes Of Health , Tebipenem Hbr Research , Development Authority , Drug Administration , Human Services , Health Media Relations , Spero Therapeutics Inc , Globenewswire Inc , Zeno Group , Department Of Health , Health Affairs , Biomedical Advanced Research , Government Agency Research , National Institute Of Allergy , Warfighter Medical Research Program Under Award No , Office Of The , Special Protocol Assessment , Chief Executive Officer , Upcoming Anticipated , Clinical Microbiology , Research Support , Assistant Secretary , Advanced Research , Joint Warfighter Medical Research Program , Infectious Diseases , Relations Contact , Investor Relations , Health Media , Consolidated Statements , Spero Therapeutics , Nc Stock Exchange , News , Information , Press Release , Hase , , Trial , F , Pr720 , N , Ontuberculous , Ycobacterial , Pulmonary , Disease , Track , Or , Top , Line , Data , Readout , Mh , 024 , Update , Status , Special , Protocol , Assessment , Agreement , Ebipenem Spro Us84833t1034 ,